{"name":"Diamant Thaci","slug":"diamant-thaci","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE1FUHIzWUVnRUNDaXR2Y2hSR0xMbWxQYm55TGZwUkdGREJWTFJpTkFudW1HWHNPRHI5SUZWdXFJeVJVWjJLVmJfcTZKVHRrQ19QV1I4eUgzTzNqTC1Qa3QxQVdaTXhIRGpCeVE?oc=5","date":"2025-08-28","type":"pipeline","source":"Wiley Online Library","summary":"Journal of the European Academy of Dermatology and Venereology - Wiley Online Library","headline":"Journal of the European Academy of Dermatology and Venereology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxOaVp3bzdIMkwxbVlqQmU1bHF0cnlDV2ZKUmJ4Y1dHeVY3MjNENmNTQlhSd1ZGZC1kTTNDYnQyUVFaTS1DckdrdENLdUl5dEVzaDYwVUx1ZkFtX0RtanVsSFpDVzBEQUJUbmx2bWgtc2JtclBYQm5MdXJDcUt5OW4tR2ZFMkQ4TEZmaTV2eTdLVHMxN1pDdjFSVFJ5QWx1TVk2THlPaHlHWGVQSVJ6ajczQlVQbVVLWm9NWFhJMmpwMmJFZDZTQlZ1cjY2RjhiR1pwWC14dEE5dHZrQmxkSm14SS1mQmJoWHNBaHhWRmtHTDZNdjh0WjhhNHR3?oc=5","date":"2025-03-11","type":"pipeline","source":"European Medical Journal","summary":"Nemolizumab in Moderate-to-Severe Atopic Dermatitis: Long-Term Safety and Efficacy and New Biomarker Insights - European Medical Journal","headline":"Nemolizumab in Moderate-to-Severe Atopic Dermatitis: Long-Term Safety and Efficacy and New Biomarker Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxPT0h3WUVzUm5wVkxFcTM3YU51TWUtZlRtSU1iY2FOZDBvOE1xdDZIVFc1aFMxZ1RXSTNoWTJpaTdfc0Q4NkdvS2Y3U1VJQVNydGR3TEszYVgwaEZWNEMtb2dJNHM3ZHVJd2otczROZ2FnUVZZR3lYQ3U4SmpoWlNwc2FOY2UtWXoxSHp2YWU3dzJadHFjT1NTa2IwRHh2b2RldGJGU3dCVm5pLV9xczdvbk1TLTFRSlh4WlNSdTZFV1B5ZUlWZWNDUjU1aTZOeG51MU8wdWxyZnNyLXFmT1dvQ2FBZE1yT2NaUjVxdFVvSE13d3p0SzRqOEo3OTh0VXlHY1VMdkNZdnh1a251TWhVdEF5Vzd5NHE0TGczX2JnLUpaeG5Kc0FjVGNvbW0?oc=5","date":"2023-11-23","type":"pipeline","source":"European Medical Journal","summary":"Bimekizumab 3-Year Efficacy in Patients with Moderate-to-Severe Plaque Psoriasis: Response Maintenance, Re-treatment, and Effect on High-Impact Areas - European Medical Journal","headline":"Bimekizumab 3-Year Efficacy in Patients with Moderate-to-Severe Plaque Psoriasis: Response Maintenance, Re-treatment, an","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE1fVXhZUFpLdmIzWHBURWlZQ0Q0UGlnY2NuN0g5WlpUdlZoN0pYNlhIczhiMXUtS1NqclVEUDB6YkVyanpSeWtwTElNS1Nqa2VYRzdsWTkxZXV1OEpoc29XNWREVkJKMWdz?oc=5","date":"2023-06-28","type":"trial","source":"Wiley Online Library","summary":"No impact of disease duration on response to tildrakizumab treatment among patients with moderate-to-severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one p","headline":"No impact of disease duration on response to tildrakizumab treatment among patients with moderate-to-severe plaque psori","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPU0pPQlFGNEVQNUtBSGcyZ00xeDJ3TmVZV2ppNnRaYnNlNUtxcEdpUy1BRFVjSDR1Q24wUDVzOW9RR0JYaWQwR1IxcVFJNVZfYWFWc091VTZ1UVVuNVpTLTlhSGMwSzRmal9RTFlkX1M1N1B0Y0ttZF9mQ0JCMnpkcVAzZEJNTWliUlhMeE1QNW1zWUNRU0Rjb19DYUFEcXZ2QlhvX3JuWk9BQQ?oc=5","date":"2023-03-27","type":"pipeline","source":"Dermatology Times","summary":"Investigational LEO Pharma IL-22 Receptor Improves EASI Scores in AD - Dermatology Times","headline":"Investigational LEO Pharma IL-22 Receptor Improves EASI Scores in AD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOSGh2dDM0WGlwVnNKRnFYclpfV3RVb2RmenVkLXRkbTdjZFdoOTVlUWlsd21GekJpWnp5Y2JlZVVJUm9yLVkzckIwVU9RZFMyWnpnZlU3cDhnM1Z4NjA5TUkyYzVvTThqanZOc2w2SUJ1UXYwbmtJXzFsWU00dGJtWHlhU1VxUTRNenBWZlV2eGlXTWY1WGlORE9ydkQ?oc=5","date":"2021-08-16","type":"regulatory","source":"pharmatimes.com","summary":"Lebrikizumab shows improvements in late-stage eczema trial - pharmatimes.com","headline":"Lebrikizumab shows improvements in late-stage eczema trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxPeHU0QV8xZUFJeE5KM3lCaktHc0dUemctUUY5YnVWZ3VYQXBFODlzWlZfa0E2Q2kyUEZ2V2ZhQ1h3MHV2bjV1bHRsWkVEeHZMejhYMXNUNFhIWGRVSV9YOVlVdzg3Y2VGM195Z2xKQXVCaHctYzgwdDN6VF9GLWdqRTZPd2lJMUJSZkhoVW5VVzluMzN6R3I3OU1JRkJzeWxCZ1I2ZlVLLVdsbmFmSncxMUlNZzNSWHVIVlVjN0QxRVUtemVJa3BRNE9R?oc=5","date":"2020-02-28","type":"pipeline","source":"European Medical Journal","summary":"Biologics in Moderate-to-Severe Psoriasis: Discover the Road to Long-term Control - European Medical Journal","headline":"Biologics in Moderate-to-Severe Psoriasis: Discover the Road to Long-term Control","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE1PMTlETDBLN1J0UGpnLW1UbWJVZUJCTThvTW5vd19qNzJwa0g2NWIxOV95UnA3T1FoMjlGdUctSENLdmdwWXlEVzRlWTl2clZ1eDd1Ry1jYnZfbHhiaWlEdA?oc=5","date":"2018-09-11","type":"trial","source":"NEJM","summary":"Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis - NEJM","headline":"Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPUVVuSWdINmh4ODZNNkNWbWJoR1pOQ0E3QUhOM2Y3c1Q0X3h3Qmx6U3Ffbm9sbWNaYWp1anlHbXJUY0l1OUFTVnhEYnBSbzcxNDJoVFp1QmFvNFhrYU5mRGpLZGo3NXlMSGRpLU0xR3lIT2l6LTFLXzZta2Jsd1N5dERJOF9NSFhMcWw2R2M4SDFYN2U5MC1mbExrcXZsTGdoS3I1c0FtNFlEdw?oc=5","date":"2018-06-07","type":"pipeline","source":"European Medical Journal","summary":"Treating Psoriasis: What Is New About Fumaric Acid Esters? - European Medical Journal","headline":"Treating Psoriasis: What Is New About Fumaric Acid Esters?","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}